Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20450567 | 1.00 | GLP1R (0.64) | GLP1RFOLH1NOD1GNPATEPHX2 | |
| SCHEMBL20450570 | 0.93 | GLP1R (0.62) | GLP1RFOLH1NOD1GNPAT | |
| SCHEMBL20450566 | 0.93 | GLP1R (0.62) | GLP1RFOLH1NOD1GNPAT | |
| SCHEMBL24592948 | 0.92 | GLP1R (0.61) | GLP1RFOLH1NOD1EPHX2 | |
| SCHEMBL23567472 | 0.92 | GLP1R (0.69) | GLP1RFOLH1NOD1EPHX2 | |
| SCHEMBL23567375 | 0.92 | GLP1R (0.61) | GLP1RFOLH1NOD1EPHX2 | |
| SCHEMBL23567741 | 0.92 | GLP1R (0.66) | GLP1RFOLH1NOD1EPHX2 | |
| SCHEMBL23567144 | 0.92 | GLP1R (0.69) | GLP1RFOLH1NOD1EPHX2 | |
| SCHEMBL23567478 | 0.92 | GLP1R (0.66) | GLP1RFOLH1NOD1EPHX2 | |
| SCHEMBL24592954 | 0.92 | GLP1R (0.61) | GLP1RFOLH1NOD1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| US-11224634-B2 | — | — | 2022-01-18 | — | — | US | disclosed |
| US-11185570-B2 | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210196791-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-22 | — | — | US | disclosed |
| US-10266578-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2018148419-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210196791-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | GLP1R 27/4885FOLH1 306/4885NOD1 3734/4885 |
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | GLP1R 27/4885FOLH1 306/4885NOD1 3734/4885 |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | GLP1R 27/4885FOLH1 306/4885NOD1 3734/4885 |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | RXFP2, RXFP1, RXFP4 | GLP1R 29/4885FOLH1 439/4885NOD1 3826/4885 |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | GLP1R 27/4885FOLH1 306/4885NOD1 3734/4885 |
| US-11224634-B2 | — | RXFP2, RXFP1, RXFP4 | GLP1R 34/4885FOLH1 346/4885NOD1 4173/4885 |
| US-10266578-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | RXFP2, RXFP1, RXFP4 | GLP1R 27/4885FOLH1 306/4885NOD1 3734/4885 |
| US-11185570-B2 | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | GLP1R 31/4885FOLH1 324/4885NOD1 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.